Next Article in Journal
MicroRNA Expression Relating to Dietary-Induced Liver Steatosis and NASH
Previous Article in Journal
Circulating microRNA Biomarkers as Liquid Biopsy for Cancer Patients: Pros and Cons of Current Assays
Previous Article in Special Issue
Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?
Article Menu

Export Article

Open AccessReview
J. Clin. Med. 2015, 4(11), 1908-1937; doi:10.3390/jcm4111908

Renin-Angiotensin-Aldosterone System Blockade in Diabetic Nephropathy. Present Evidences

Division of Nephrology, Department of Internal Medicine, Fuenlabrada University Hospital, Rey Juan Carlos University School of Medicine, Camino del Molino, 2, 28942 Fuenlabrada, Madrid, Spain
*
Author to whom correspondence should be addressed.
Academic Editors: Juan F. Navarro-González and Desirée Luis
Received: 30 March 2015 / Revised: 27 May 2015 / Accepted: 15 October 2015 / Published: 9 November 2015
(This article belongs to the Special Issue Diabetic Nephropathy)
View Full-Text   |   Download PDF [305 KB, uploaded 9 November 2015]

Abstract

Diabetic Kidney Disease (DKD) is the leading cause of chronic kidney disease in developed countries and its prevalence has increased dramatically in the past few decades. These patients are at an increased risk for premature death, cardiovascular disease, and other severe illnesses that result in frequent hospitalizations and increased health-care utilization. Although much progress has been made in slowing the progression of diabetic nephropathy, renal dysfunction and the development of end-stage renal disease remain major concerns in diabetes. Dysregulation of the renin-angiotensin-aldosterone system (RAAS) results in progressive renal damage. RAAS blockade is the cornerstone of treatment of DKD, with proven efficacy in many arenas. The theoretically-attractive option of combining these medications that target different points in the pathway, potentially offering a more complete RAAS blockade, has also been tested in clinical trials, but long-term outcomes were disappointing. This review examines the “state of play” for RAAS blockade in DKD, dual blockade of various combinations, and a perspective on its benefits and potential risks. View Full-Text
Keywords: renin-angiotensin-aldosterone system blockade; combined RAAS blockade; dual RAAS blockade; diabetic nephropathy; diabetic kidney disease; ACE inhibitors; angiotensin receptor blockers; direct renin inhibitors; mineralocorticoid receptor antagonists; aldosterone antagonist renin-angiotensin-aldosterone system blockade; combined RAAS blockade; dual RAAS blockade; diabetic nephropathy; diabetic kidney disease; ACE inhibitors; angiotensin receptor blockers; direct renin inhibitors; mineralocorticoid receptor antagonists; aldosterone antagonist
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Lozano-Maneiro, L.; Puente-García, A. Renin-Angiotensin-Aldosterone System Blockade in Diabetic Nephropathy. Present Evidences. J. Clin. Med. 2015, 4, 1908-1937.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top